Last updated: February 16, 2026
What Is the Market Status of NDC 00169-4505?
NDC 00169-4505 represents a drug marketed as Doxil® (liposomal doxorubicin). It is approved primarily for ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. Doxil® has faced biosimilar competition since 2017, affecting its market share.
How Has the Market for Doxil® Changed in Recent Years?
Doxil®’s revenue declined post-2017 due to biosimilar entrants and increased genericization. In 2022, sales in the U.S. totaled approximately $200 million, down from a peak of $400 million in 2015. The drug’s high cost, typically $10,000–$15,000 per treatment course, remains a high barrier.
The biosimilar market has grown, with multiple generic versions approved by the FDA. Its impact is growing in the U.S., Europe, and emerging markets, driving price competition.
What Are Current Pricing Trends and Projections?
Current Pricing
In the U.S., list prices for the original Doxil® range from $9,000 to $14,000 per treatment course. Commercial insurance often negotiates discounts, reducing patient costs significantly.
Price Competition and Biosimilar Impact
- Generic biosimilars, approved since 2017, are priced 20-30% below the originator.
- Emerging biosimilars are priced approximately $6,000–$10,000 per course.
- The entry of biosimilars has compressed prices by an estimated 25% since 2017.
Future Price Projections
Analysts project:
- Biosimilar competition to stabilize at a 25–35% discount to the originator over the next 5 years.
- A gradual decline in the average treatment course price to around $8,000 for the originator and about $6,500 for biosimilars by 2028.
- The overall market to decrease in value by roughly 20–30% due to price erosion and market share shifts.
Market Outlook
- Continued biosimilar proliferation limits the originator’s market dominance.
- Growth in emerging markets and expansion into new indications may stabilize or slightly increase sales.
- Disruptions may occur if new formulations or combination therapies are approved.
What Are Key Market Drivers and Barriers?
Drivers
- Increasing prevalence of ovarian and multiple myeloma.
- Growing adoption of biosimilars driven by cost-effectiveness.
- Price reductions from payers negotiating discounts.
Barriers
- Limited adoption in low-income regions.
- Regulatory and reimbursement hurdles for biosimilars.
- Intellectual property rights extending potential exclusivity for certain markets.
Summary Table of Revenue and Price Expectations
| Year |
Estimated Revenue (USD) |
Average Price per Course (USD) |
Market Share of Biosimilars |
Remarks |
| 2022 |
200 million |
9,000 – 14,000 |
30–40% |
Biosimilar presence growing |
| 2023-2025 |
Slight decline |
8,000 – 13,000 |
40–50% |
Price competition continues |
| 2026-2028 |
140–160 million |
6,500 – 9,000 |
60%+ |
Shift toward biosimilar usage |
Key Takeaways
- Doxil® (NDC 00169-4505) faces sustained market erosion due to biosimilar competition.
- Prices are projected to decline 25–30% over five years, with a plateauing effect in the late 2020s.
- Revenue projections demonstrate a reduction, driven by competitive pricing and market share shifts.
- Market expansion into emerging regions and new indications may partially offset declines.
- Major barriers remain in access and reimbursement, especially outside developed markets.
Frequently Asked Questions
1. How has biosimilar approval affected Doxil® sales?
Biosimilar approvals since 2017 have led to a 25% reduction in prices and a significant share of the market being captured by biosimilars, decreasing originator sales.
2. What are the main markets for Doxil®?
The U.S., Europe, and Japan are key markets, with emerging markets gradually adopting biosimilars.
3. Are there new formulations or indications in development for this drug?
No significant new formulations are currently under regulatory review; focus remains on biosimilar development.
4. How do pricing strategies differ between originator and biosimilars?
Biosimilars are generally priced 20–30% lower than the originator, with discounts increasing as market penetration grows.
5. What factors could alter the current price and market projection?
Regulatory changes, patent litigation, new therapeutic indications, or breakthroughs in alternative treatments could influence future dynamics.
Citations
[1] IQVIA, "IMS Market Data," 2022.
[2] FDA, Biosimilar Approvals, 2017–2023.
[3] Evaluate Pharma, "Worldwide Market Analysis," 2023.
[4] ReportLinker, "Biosimilar Market Trends," 2022.
